Baidu
map

Sci Rep:在雄激素抵抗前列腺癌中, REST是一个在类EMT和干细胞表型的获得中的关键调控因子

2017-04-02 AlexYang MedSci原创

雄激素抵抗性前列腺癌(CPRC),同样也称为激素难治性前列腺癌(HRPC),需要引起人们适当的注意,因为它不仅对雄激素阻断治疗、化疗和放疗有抗性,而且还具有高度可转移性特点。越来越多的证据显示,神经内分泌细胞(NE)的富集和CRPC有关。最近,研究人员通过直接的Twist1和CD44转录的抑制,结合RNA-seq和CHIP-seq分析,阐释了REST参与了上皮间质转化(EMT)和NE分化的前列腺癌

雄激素抵抗性前列腺癌(CPRC),同样也称为激素难治性前列腺癌(HRPC),需要引起人们适当的注意,因为它不仅对雄激素阻断治疗、化疗和放疗有抗性,而且还具有高度可转移性特点。越来越多的证据显示,神经内分泌细胞(NE)的富集和CRPC有关。

最近,研究人员通过直接的Twist1和CD44转录的抑制,结合RNA-seq和CHIP-seq分析,阐释了REST参与了上皮间质转化(EMT)和NE分化的前列腺癌细胞细胞(PCa)干细胞特性的获得。特别地,研究人员展示了短期REST敲除诱导了LNCaP细胞的NE分化,而对应的长期REST敲除增强了Twist1和CD44的表达、细胞迁移和球体形成。研究还指出,在雄激素抵抗的CWR22Rv1 PCa细胞中,REST的超表达可以显着的减少Twist1和CD44的表达、细胞迁移和球体形成。最后,研究人员指出,该研究揭示了REST在NE PCa细胞中对EMT和干细胞特性的调控作用,并表明了REST是CRPC药物作用的潜在靶点的观点。

原始出处:

Yi-Ting Chang, Tzu-Ping Lin, Mel Campbell et al. REST is a crucial regulator for acquiring EMT-like and stemness phenotypes in hormone-refractory prostate cancer. Sci Rep. 03 March 2017. doi:10.1038/srep42795

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2050632, encodeId=099b20506322b, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Dec 31 22:00:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462124, encodeId=8c4f1462124c8, content=<a href='/topic/show?id=c6436e385a' target=_blank style='color:#2F92EE;'>#EMT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6738, encryptionId=c6436e385a, topicName=EMT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f216475172, createdName=lfcmxl, createdTime=Mon Apr 03 15:00:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535127, encodeId=1922153512eca, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Mon Apr 03 15:00:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184730, encodeId=ed40184e305b, content=还不是很了解,需要进一步学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40011656268, createdName=121485632188547785, createdTime=Mon Apr 03 01:30:46 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184729, encodeId=fa36184e29e8, content=不甚了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40011656268, createdName=121485632188547785, createdTime=Mon Apr 03 01:30:27 CST 2017, time=2017-04-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2050632, encodeId=099b20506322b, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Dec 31 22:00:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462124, encodeId=8c4f1462124c8, content=<a href='/topic/show?id=c6436e385a' target=_blank style='color:#2F92EE;'>#EMT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6738, encryptionId=c6436e385a, topicName=EMT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f216475172, createdName=lfcmxl, createdTime=Mon Apr 03 15:00:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535127, encodeId=1922153512eca, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Mon Apr 03 15:00:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184730, encodeId=ed40184e305b, content=还不是很了解,需要进一步学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40011656268, createdName=121485632188547785, createdTime=Mon Apr 03 01:30:46 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184729, encodeId=fa36184e29e8, content=不甚了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40011656268, createdName=121485632188547785, createdTime=Mon Apr 03 01:30:27 CST 2017, time=2017-04-03, status=1, ipAttribution=)]
    2017-04-03 lfcmxl
  3. [GetPortalCommentsPageByObjectIdResponse(id=2050632, encodeId=099b20506322b, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Dec 31 22:00:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462124, encodeId=8c4f1462124c8, content=<a href='/topic/show?id=c6436e385a' target=_blank style='color:#2F92EE;'>#EMT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6738, encryptionId=c6436e385a, topicName=EMT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f216475172, createdName=lfcmxl, createdTime=Mon Apr 03 15:00:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535127, encodeId=1922153512eca, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Mon Apr 03 15:00:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184730, encodeId=ed40184e305b, content=还不是很了解,需要进一步学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40011656268, createdName=121485632188547785, createdTime=Mon Apr 03 01:30:46 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184729, encodeId=fa36184e29e8, content=不甚了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40011656268, createdName=121485632188547785, createdTime=Mon Apr 03 01:30:27 CST 2017, time=2017-04-03, status=1, ipAttribution=)]
    2017-04-03 tastas
  4. [GetPortalCommentsPageByObjectIdResponse(id=2050632, encodeId=099b20506322b, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Dec 31 22:00:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462124, encodeId=8c4f1462124c8, content=<a href='/topic/show?id=c6436e385a' target=_blank style='color:#2F92EE;'>#EMT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6738, encryptionId=c6436e385a, topicName=EMT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f216475172, createdName=lfcmxl, createdTime=Mon Apr 03 15:00:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535127, encodeId=1922153512eca, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Mon Apr 03 15:00:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184730, encodeId=ed40184e305b, content=还不是很了解,需要进一步学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40011656268, createdName=121485632188547785, createdTime=Mon Apr 03 01:30:46 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184729, encodeId=fa36184e29e8, content=不甚了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40011656268, createdName=121485632188547785, createdTime=Mon Apr 03 01:30:27 CST 2017, time=2017-04-03, status=1, ipAttribution=)]
    2017-04-03 121485632188547785

    还不是很了解,需要进一步学习。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2050632, encodeId=099b20506322b, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Dec 31 22:00:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462124, encodeId=8c4f1462124c8, content=<a href='/topic/show?id=c6436e385a' target=_blank style='color:#2F92EE;'>#EMT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6738, encryptionId=c6436e385a, topicName=EMT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f216475172, createdName=lfcmxl, createdTime=Mon Apr 03 15:00:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535127, encodeId=1922153512eca, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Mon Apr 03 15:00:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184730, encodeId=ed40184e305b, content=还不是很了解,需要进一步学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40011656268, createdName=121485632188547785, createdTime=Mon Apr 03 01:30:46 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184729, encodeId=fa36184e29e8, content=不甚了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40011656268, createdName=121485632188547785, createdTime=Mon Apr 03 01:30:27 CST 2017, time=2017-04-03, status=1, ipAttribution=)]
    2017-04-03 121485632188547785

    不甚了解

    0

相关资讯

Nat Med:单独使用anti-CTLA4治疗前列腺癌效果差的原因

此项临床研究,阐明了anti-CTLA4疗法在对于治疗前列腺癌症疗效差的原因。发现了PD-L1以及VISTA的表达量在anti-CTLA4疗法后的表达量的上升。暗示了采用多种针对check point信号的疗法(anti-PD-L1, anti-VISTA)共同治疗前列腺癌症疗的效果可能更好。为下一步开发新的疗法提供了数据。

Cancer Cell:ERG基因拟肽类抑制剂用于治疗前列腺癌

转录因子在多种癌症的发展中发挥关键作用,而对治疗靶向的治疗仍然是一个挑战。在前列腺癌中,编码转录因子ERG的基因被重新排列并在前列腺癌发生中发挥关键作用。在这项研究中,研究人员利用大分子多肽来靶向ERG,他们在细胞系和动物模型中证明这种方法可以有效靶向并促进ERG融合蛋白的降解,对细胞正常功能几乎不会产生影响。

Oncogene:脑发育蛋白/EB3通路促进前列腺癌侵入活性

前列腺癌是男性群体中常见的癌症,并且目前的转移性前列腺癌无法治愈。最近,研究人员在研究中展示了drebrin/EB3通路协调了动态微管/肌动蛋白丝与响应导向因子的潜在细胞性状变化的交流 ,且该通路在前列腺癌细胞侵入中有重要作用。研究发现,在良性人类前列腺中,脑发育蛋白(drebrin)限制在基部上皮细胞中表达;而在恶性前列腺癌症病灶中,该蛋白在内腔上皮细胞中表达上调。研究还发现,脑发育蛋白在人类前

Sci Rep:受ELF5调节的AR激活可以调控前列腺癌的进展

转录因子的类E74因子5(ELF5)是一个有效的抗癌基因,它可以防止上皮-间质转化(EMT)和前列腺癌(PCa)的转移。然而,对于它如何抑制肿瘤的生长和是否它能够与雄激素受体(AR)互作却知道的很少。最近,研究人员发现,ELF5在AR激活的PCa细胞中频繁表达。并且,在PCa细胞中,ELF5可以和AR结合,扮演一个生理的伙伴角色,并且ELF5可负调控AR的转录活性。另外,研究还发现,ELF5与AR

The Lancet Oncology:前列腺癌患者术后生活质量调查

如何选择早期前列腺癌的治疗方案极大影响患者的预后生活质量

Sci Rep:RNF7敲除可以通过钝化ERK1/2通路来抑制前列腺癌肿瘤发生

去雄抗性的发展是导致前列腺癌病人致死的一个关键的因素。环指蛋白7(RNF7)在癌细胞中的高表达在肿瘤的发展过程中起着关键的角色。然而,RNF7在前列腺癌症发展过程中的角色并没有很好的阐释。最近,研究人员就RNF7在前列腺癌发生中的相关作用进行了研究。在研究中,研究人员在两个去雄抗性前列腺癌细胞系中,分别是DU145和PC3,利用shRNA干扰沉默了RNF7表达。研究人员发现,RNF7的敲除可以减弱

Baidu
map
Baidu
map
Baidu
map